Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2017

Collaboration Agreement [Abstract]

Collaboration revenue with related party

The collaboration revenue the Company earned from Sanofi is detailed below:

	Three Months Ended March 31,
Sanofi Collaboration Revenue	2017			2016
Antibody:
Reimbursement of Regeneron research and development expenses	$	155,245		$	193,602
Reimbursement of Regeneron commercialization-related expenses	73,559			68,722
Regeneron's share of losses in connection with commercialization of antibodies	(108,402		)	(99,422		)
Other	11,286			7,517
Total Antibody	131,688			170,419
Immuno-oncology:
Reimbursement of Regeneron research and development expenses	58,679			29,275
Other	20,000			20,000
Total Immuno-oncology	78,679			49,275
	$	210,367		$	219,694

Collaboration revenue

The collaboration revenue the Company earned from Bayer is detailed below:

	Three Months Ended March 31,
Bayer Collaboration Revenue	2017		2016
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	174,876	$	145,835
Cost-sharing of Regeneron EYLEA development expenses	2,451		2,743
Other	10,603		26,492
Total EYLEA	187,930		175,070
PDGFR-beta antibody:
Cost-sharing of rinucumab/aflibercept (REGN2176-3) development expenses	1,857		1,896
Other	13		2,626
Total PDGFR-beta antibody	1,870		4,522
Ang2 antibody:
Cost-sharing of nesvacumab/aflibercept (REGN910-3) development expenses	2,041		—
Other	2,098		—
Total Ang2 antibody	4,139		—
	$	193,939	$	179,592